BeOne Medicines (ONC) announced that the U.S. FDA has granted Breakthrough Therapy Designation for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. Additionally, the FDA has accepted BeOne’s request for participation in Project Orbis, an initiative that provides a framework for concurrent submission and review of oncology products among participating global health authorities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines initiated with an Overweight at Barclays
- Optimistic Buy Rating for BeOne Medicines Driven by Promising Sonrotoclax Trial Results and Market Potential
- BeOne Medicines reports ‘positive’ results from Phase 1/2 study of sonrotoclax
- BeOne Medicines announces EC approved Tevimbra to treat NSCLC
- Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen